Gene interactions and pathways from curated databases and text-mining

◀ Back to CXCL12

CXCL12 — CXCR3

Pathways - manually collected, often from reviews:

Text-mined interactions from Literome

Amara et al., J Biol Chem 1999 : Importantly, the amino-terminal domain of SDF-1alpha which is required for binding to, and activation of, CXCR4 remains exposed after binding to HS and is recognized by a neutralizing monoclonal antibody directed against the first residues of the chemokine
Lande et al., J Immunol 2004 (Arthritis...) : We also show that CXCR3 and CXCR4 are expressed by both blood derived pDCs and pDCs isolated from RA and PA SF and that CXCL-10, CXCL-11, and CXCL-12 present in RA and PA SF stimulate chemotaxis of blood derived pDCs
Hu et al., Circulation 2007 (Anoxia...) : In isolated myocytes, CXCR4 activation by SDF-1alpha resulted in increased phosphorylation of both ERK 1/2 and AKT and decreased phosphorylation of JNK and p38
Sierro et al., Proc Natl Acad Sci U S A 2007 : CXCL12 did not induce signaling through CXCR7 ; however, CXCR7 formed functional heterodimers with CXCR4 and enhanced CXCL12 induced signaling
Jopling et al., Br J Pharmacol 2007 : Surface CXCR3 expression was specifically decreased in response to CXCL9, CXCL10 and CXCL11
Mukherjee et al., Cell Mol Immunol 2008 : The oligomer induced the expression of CXCR3 , associated with B cell activation, while the monomer induced the expression of CXCL4 , a powerful angiostatic chemokine
Groom et al., Immunol Cell Biol 2011 : CXCR3 is activated by three interferon ( IFN ) -?-inducible ligands CXCL9 ( monokine induced by gamma-interferon ), CXCL10 ( interferon induced protein-10 ) and CXCL11 ( interferon-inducible T-cell alpha chemoattractant )
Korniejewska et al., Immunology 2011 : Surprisingly, and in contrast with the other CXCR3 agonists, stimulation of T lymphocytes with CXCL4 failed to elicit migratory responses and did not lead to loss of surface CXCR3 expression
Duda et al., Clin Cancer Res 2011 (Neoplasms) : CXCL12 ( SDF1alpha ) -CXCR4/CXCR7 pathway inhibition : an emerging sensitizer for anticancer therapies ?
Groom et al., Exp Cell Res 2011 : CXCR3 is activated by three interferon-inducible ligands CXCL9 ( MIG ), CXCL10 ( IP-10 ) and CXCL11 ( I-TAC )
Romagnani et al., Clin Chim Acta 2012 : By binding to its specific cognate receptor CXCR3 , CXCL10 critically regulates chemotaxis during several immune-inflammatory processes
Wang et al., Cancer Lett 2013 (Neoplasms) : This report reviews the mechanisms of CXCL4/PF-4 angiostatic activity, including interference with angiogenic growth factors bFGF-2 and VEGF165, activation of CXCR3B , interactions with integrins, interference with cell cycle, interactions with factors such as VEGF121 and CXCL8/IL-8, and derived molecules of CXCL4/PF-4 with angiostatic and anti-tumoral activities in different models in vivo or in vitro
Mueller et al., PloS one 2013 (Immunologic Deficiency Syndromes...) : Upon stimulation by the endogenous ligand CXCL12 , CXCR4 becomes phosphorylated at multiple sites in its C-terminal domain